Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enanta Pharmaceuticals, Inc.

https://www.enanta.com/home/default.aspx

Latest From Enanta Pharmaceuticals, Inc.

Terns Raises $87m More For NASH R&D, Including Lilly Equity Purchase

In its third venture funding round, Terns adds backing from Deerfield in addition to Lilly’s investment. It licensed three non-alcoholic steatohepatitis candidates from the big pharma in 2018.

Financing Business Strategies

Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate

Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine

Deals Business Strategies

Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.

Commercial Companies

Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy

A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register